Stver Lehmann Consulting By Manon Stver Matthieu Lehmann
Stöver Lehmann Consulting By Manon Stöver Matthieu Lehmann Lausanne, June 23 rd 2006 Stöver Lehmann Consulting
Agenda w Who are we ? w Why are we here today ? w What has been done until today? w What can be achieved and how? Stöver Lehmann Consulting 1
SLC – Team presentation w Manon Stöver w Co-founder w Expertise in investment within the Petroleum Industry w Matthieu Lehmann w Co-founder w Expertise in Biotechnologies and Process Development Stöver Lehmann Consulting 2
SLC - Philosophy w Our orientation is to raise funds for refreshing and interesting research and development w Our vision is to support ideas with huge potential for humanity w We are looking for revolution more than evolution Stöver Lehmann Consulting 3
SLC – Past Successes w SLC’s past successes in raising funds are in the field of research and development: w Bio. Xell (Cancer therapy) w 7 TM Pharma (Virology) w H 2 FUEL (hydrogen engine) w Hydro. NEXT (biofuel cell) Stöver Lehmann Consulting 4
Dr. de Grey’s presentation w Engineering background from computer sciences w Previous work in bioinformatics w Current research in biogerontology w His vision: Reengineering the approach of how to cure aging Stöver Lehmann Consulting 5
What is Unlimited Life? w A research institute in biogerontology w A concept: Curing aging Gerontology Metabolism Engineering Damage Geriatrics Pathology w The final mission of UL is to provide people with medecines to cure aging Stöver Lehmann Consulting 6
More about Unlimited Life w Home institution for research is Cambridge w Research is highly potential for several breakthroughs : ‘We are already on the road, it’s definitely more than a simple concept !’ w Absolutely refreshing approach of anti-aging process: start at the roots of the process w At the beginning of something revolutionary Stöver Lehmann Consulting 7
The 7 deadly things principle w Basics of Dr. de Grey research w Damages rising with age 1. Cell loss, cell atrophy 2. Nuclear [epi]mutations (only cancer matters) 3. Mutant mitochondria 4. Death-resistant cells 5. Extracellular crosslinks 6. Extracellular junk 7. Intracellular junk Stöver Lehmann Consulting 8
Today’s Focus w Advise to improve funding of Unlimited Life research Why are we concerned ? w We believe in our customer competencies w We may change the world w Aging is the most fatal and the first cause of death on Earth w Life is a gift, we must fight to keep it as hard as we fight for our freedom Stöver Lehmann Consulting 9
Competitive Anti-Aging Researches w Current technologies to slow the aging process w Cryonic therapy w Chemical drugs (DHEA) w Medicines based on proteins w Plastic surgery w Vitamins and food supplements Stöver Lehmann Consulting 10
Results for current Anti-Aging w Results obtained from research w Slowing down the process of aging w Mask the external signs of aging w Small improvement on the origin of aging process w None of these technology treated aging from its roots w NB! These technologies are not competitive with the results of Dr. de Grey’s research Stöver Lehmann Consulting 11
Origin of previous raised funds w Past funds w Winning the Mprize: donations for continuing research w Expenses contributions w Donation of Air miles w Who are these investors ? w Individuals w Foundations Stöver Lehmann Consulting 12
Money raised from these funds w Funds raised w Mprize: $ 3. 5 million w Donations: $ 218’ 005 w Cost expenses: $ 89’ 756 w Air miles: 360’ 374 miles Good starting point but obviously not enough ! Stöver Lehmann Consulting 13
Dr. de Grey’s request for funding w Dr. de Grey objectives: w $100 M/year of funding for the next 10 years w Creating research institutes all over the world w Investors are not to draw any direct benefit from providing funding Stöver Lehmann Consulting 14
Possible solutions w Organizational improvements w Promotion improvements w Improvement of current funding ways w New funding ways Stöver Lehmann Consulting 15
Organizational improvements w Organizational aspect w Define milestones/targets w Build a team w Find a ‘face’ for funding leader Stöver Lehmann Consulting 16
Promotion improvements w Generate publicity w Newspapers w Broadcasting of documentaries w Universities w Advertisements w Exhibition w Nobel price for medicine Stöver Lehmann Consulting 17
Improvement of current funding ways w Donations w Other foundations w Individuals w Air miles Stöver Lehmann Consulting 18
Foundations and Individuals w Aim at other foundations: w w AIDS association Cancer therapy association Arthritis Foundation Biological Trust w Convince individuals: w Wealthy philanthropic people Stöver Lehmann Consulting 19
Airmiles Change the law w Airline companies might write off their airmiles older than 20 y to foundations w Opportunity to raise billions of airmiles w Very convenient for both parties Stöver Lehmann Consulting 20
New funding ways w Business Angels w Open source research w Partnerships w VCs Stöver Lehmann Consulting 21
Business angels w With certain characteristics: w High personal interest in the research w Diversifying his/her investments w Maybe (s)he will give a billion w Examples w w Donald Trump Hugh Hefner Bill Gates Larry Ellison Stöver Lehmann Consulting 22
Larry Ellison w Founder of Oracle w Almost as wealthy as Bill Gates w Human benefactor w What is more prestigious than investing in first cause of death Stöver Lehmann Consulting 23
Open source w No profits involvement w Access to a huge community w Low and shared cost w Increase in time efficiency and productivity w High demanding process from a controlling aspect Stöver Lehmann Consulting 24
Open source in our case w Applicable on secondary level of research w Set up an association with confidential agreement w Create different virtual institutes around the world Stöver Lehmann Consulting 25
Partnership w Partners w w Cooperation in research; such as Cryogenics Set up subsidiaries with pharmaceuticals VCs with pharmaceuticals in the portfolio Business angels with certain interests w To attract partners: certain level of leverage needed w Define milestones/targets w Create a source of revenues Stöver Lehmann Consulting 26
Venture Capitalist w Involvement in the management and the ownership w Huge amount money can be brought on the table w Examples w w w Cardinal Partners Polaris Venture Partners Techno Venture Management Novartis Bioventures Fund Cargill Ventures Three Arch Partners Stöver Lehmann Consulting 27
Funding schedule First two years w Research set up w Define milestones/targets for third parties w Alliances with anti-aging clinics to set up globally research institutes at universities w Create a team w Use of benefits of an open source research w Funds w Foundations and prices w Business Angels w Adjust budget Stöver Lehmann Consulting 28
Funding schedule Next three years w Involvement of VCs w Creating revenues (seminars, meetings, publishing books, magazines) w Partnership with pharmaceutical companies regarding first mover advantage for commercial use Stöver Lehmann Consulting 29
Financial Scheme - Sources Year 1 Year 2 Year 3 Year 4 Year 5 Donations 0. 2 0. 4 0. 5 VCs - - 2. 1 6. 9 6. 8 BAs 4. 3 2. 0 Others 0. 5 0. 6 0. 7 Total 5 5 5 10 10 Stöver Lehmann Consulting 30
Financial scheme - Uses Current expenditures Promotion Publishing Research Others Year 1 0. 1 Year 2 0. 1 Year 3 0. 1 Year 4 0. 1 Year 5 0. 1 4. 5 0. 2 0. 5 0. 2 9 0. 2 Stöver Lehmann Consulting 31
Conclusion w We have investigated possibilities for funding w within the requests w outside the requests w Who dares wins… Stöver Lehmann Consulting 32
Thank for your attention Manon Stöver: manonstover@gmail. com Matthieu Lehmann matthieu. lehmann@epfl. ch Stöver Lehmann Consulting
- Slides: 34